Dicerna to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences in September.

• H.C. Wainwright 20th Annual Global Investment Conference, Wednesday, September 5, 2018 at 1:45 p.m. ET, at The St. Regis in New York. Dr. Fambrough will present a corporate update and overview of the Company’s most advanced GalXC™ pipeline programs, including DCR-PHXC, an investigational RNAi therapeutic in development for the treatment of all forms of primary hyperoxaluria. A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.
• Citi’s 13th Annual Biotech Conference, Thursday, September 6, 2018, in Boston. Dr. Fambrough will be available for one-on-one meetings with investors at the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180829005101/en/

Investors:
Rx Communications Group
Paula Schwartz, 917-322-2216
[email protected]
or
Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
[email protected]

Source: Dicerna Pharmaceuticals, Inc.

You May Also Be Interested In

• Agarwoodie Launches Jewelry Line Using 100% Pure, 300-Year-Old Wild Indonesian Agarwood
• ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
• GAM special situations managers cross 5% ownership threshold in Liontrust and build a position in Impax, citing continued engagement and deep undervaluation